Bristol Myers pays $350M upfront for rights to heart drug Camzyos in Asia
Bristol Myers Squibb is setting up a deal with Shanghai-based LianBio to get the rights to the heart drug Camzyos in China and several other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
